No Pill for This: The Lived Reality of Cocaine and Meth Recovery

The opioid crisis reshaped American medicine in one crucial way: it made pharmacotherapy a mainstream conversation. Buprenorphine. Methadone. Naltrexone. These words now appear in insurance authorization forms, state budgets, and congressional testimony. The existence of FDA-approved medication for opioid use disorder (OUD) — imperfect as access remains — represents a hard-won clinical foundation that the field can build on.

For people whose primary substance is cocaine or methamphetamine, that foundation does not exist.

As of May 2026, the FDA has approved zero medications for cocaine use disorder or methamphetamine use disorder. There is no pharmacological equivalent of buprenorphine for the stimulant-using population — a group that NIDA estimates at over 2.5 million Americans with a diagnosable stimulant use disorder (SUD). Stimulant-related deaths reached 57,500 in 2022, with approximately 70% involving fentanyl contamination, complicating both treatment and harm reduction.

That treatment gap — large, stubborn, and poorly publicized compared to the opioid crisis — falls primarily on two interventions: contingency management (CM) and peer recovery support services (PRSS). And the people delivering both are, increasingly, people who have lived the experience of stimulant addiction themselves.

What “No Medication” Actually Means for a Person in Recovery

To understand why this matters, consider the experience of someone with opioid use disorder who enters treatment versus someone with cocaine use disorder. The person with OUD can receive buprenorphine on day one — a medication that directly binds opioid receptors, reduces craving, prevents withdrawal, and dramatically lowers overdose risk. Clinical guidelines, Medicaid coverage, and telehealth delivery have made this increasingly accessible.

For a person with cocaine use disorder, day one looks different. There is no medication to manage withdrawal directly (though withdrawal from cocaine is rarely medically dangerous, it is psychologically grueling — the “crash” of profound fatigue, dysphoria, and anhedonia lasting days to weeks). There is no medication to reduce craving reliably. The treatment recommendation, broadly, is: behavioral therapy. Come back weekly. Stick with it.

People do recover from stimulant use disorders — the research is clear on this. But the path is steeper, the clinical infrastructure thinner, and the treatment retention rates lower than for OUD.

Contingency Management: The Evidence-Based Tool That Keeps Getting Blocked

Contingency management is the most robustly evidence-based behavioral treatment for stimulant use disorders. Participants earn vouchers or prizes for providing drug-negative urine samples. The behavioral reinforcement mechanism — tangible positive rewards for sobriety — is straightforward and, across dozens of clinical trials, it works.

A 2024 analysis of 13 randomized clinical trials involving over 2,000 participants found that 18% of people in stimulant use disorder treatment reduced their primary drug use (compared to 14% who achieved abstinence outright). More critically, the study found that reducing use — not just full abstinence — was associated with meaningful improvements: lower craving, less depression, improved functioning. This “harm reduction through reduction” framing matters, because it moves the goalposts from an all-or-nothing standard that sets people up to see relapse as failure.

Despite the evidence, CM has faced consistent political and logistical obstacles in the United States. The core objection: paying people to not use drugs feels counterintuitive to policymakers. The result has been a patchwork — Colorado, California, and a handful of other states cover CM through Medicaid; most do not. An active 2026 clinical trial (withpower.com) is recruiting participants to continue building the evidence base, but the policy gap remains wider than the science gap.

Peer Support: Where Lived Experience Becomes Clinical Infrastructure

Into the space that pharmacotherapy cannot fill, peer recovery support specialists (PRSS) have moved — and they are filling it with something medications cannot provide: credibility born from having been there.

Peer support specialists must attest that they have lived experience with a substance use disorder, a mental health condition, or a co-occurring disorder. Their ability to share their own story — to sit across from someone in acute withdrawal or early recovery and say I know what this actually feels like — is not incidental to the work. It is the therapeutic mechanism.

Peer support specialists must attest that they have lived experience with a substance use disorder, a mental health condition, or a co-occurring disorder.

A systematic review published in Frontiers in Psychology found that PRSS are associated with reduced substance use and relapse rates, improved relationships with treatment providers, increased treatment retention, and greater treatment satisfaction across settings. These are meaningful clinical outcomes delivered by a workforce that the traditional health system trained and credentialed only recently.

The expansion is visible: certification programs in California, Minnesota, Connecticut, and DC are all adding capacity in 2026, with scholarship support for people who cannot cover tuition. HRSA’s Behavioral Workforce Training grant is funding university programs. The SAMHSA BRSS-TACS technical assistance center has made PRSS workforce development a central priority.

Importantly, peer support is not a lesser treatment because it lacks a pharmacological mechanism. For stimulant use disorders, it may be the primary treatment — and the people doing it know that.

On the Horizon: GLP-1s and the Possibility of a Pharmacotherapy

The most significant recent development in stimulant pharmacotherapy research has nothing to do with traditional addiction medicine. A March 2026 BMJ study analyzing more than 600,000 U.S. veterans found that those taking GLP-1 receptor agonist medications (semaglutide, liraglutide) had a 14% to 25% lower risk of developing substance use disorders — a finding that spanned alcohol, opioids, cannabis, cocaine, and nicotine.

The mechanistic hypothesis: GLP-1 medications appear to modulate dopamine reward pathways in the brain, reducing the salience of rewarding stimuli — including drugs. A San Francisco clinical trial is currently evaluating semaglutide specifically for methamphetamine use disorder.

This is early-stage. The BMJ study was observational. GLP-1s are not approved for addiction, and the cost barriers are substantial (list prices around $800-$1,000/month before insurance). But for a field where the pharmacotherapy pipeline for stimulants has been largely empty for decades, the GLP-1 signal represents genuine scientific hope.

Why This Matters for People in Recovery

If you are seeking recovery from cocaine or methamphetamine use — for yourself or someone you care about — the treatment landscape requires navigating more actively than the OUD landscape does. There is no single medication to anchor a conversation with a doctor. What works is behavioral: structured programs, peer support, contingency management, and sustained engagement.

That landscape is not hopeless. Recovery rates for stimulant use disorders, when people stay engaged in treatment, are real and documented. The tools exist. The challenge is access, stigma, and a health system that is only beginning to build the infrastructure for stimulant recovery that it built, painfully slowly, for opioid recovery.

Finding a provider who understands stimulant use disorders, a peer support specialist who shares lived experience, or a program that uses contingency management is the practical next step — and Rize is designed to help you find exactly that.

Search facilities near you that treat stimulant use disorders →

Explore more on substance use and recovery and lived experience in addiction.